- Home
- LDWY vs ALZN Comparison
LDWY vs ALZN Comparison
Compare LDWY & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- ALZN
- Stock Information
- Founded
- LDWY 1990
- ALZN 2016
- Country
- LDWY United States
- ALZN United States
- Employees
- LDWY N/A
- ALZN N/A
- Industry
- LDWY Advertising
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- LDWY Consumer Discretionary
- ALZN Health Care
- Exchange
- LDWY Nasdaq
- ALZN Nasdaq
- Market Cap
- LDWY 9.2M
- ALZN 7.4M
- IPO Year
- LDWY 1991
- ALZN 2021
- Fundamental
- Price
- LDWY $5.15
- ALZN $2.62
- Analyst Decision
- LDWY
- ALZN Strong Buy
- Analyst Count
- LDWY 0
- ALZN 1
- Target Price
- LDWY N/A
- ALZN $45.00
- AVG Volume (30 Days)
- LDWY 5.7K
- ALZN 78.7K
- Earning Date
- LDWY 08-28-2025
- ALZN 09-10-2025
- Dividend Yield
- LDWY N/A
- ALZN N/A
- EPS Growth
- LDWY N/A
- ALZN N/A
- EPS
- LDWY 1.66
- ALZN N/A
- Revenue
- LDWY $71,244,000.00
- ALZN N/A
- Revenue This Year
- LDWY N/A
- ALZN N/A
- Revenue Next Year
- LDWY N/A
- ALZN N/A
- P/E Ratio
- LDWY $3.18
- ALZN N/A
- Revenue Growth
- LDWY 187.12
- ALZN N/A
- 52 Week Low
- LDWY $3.02
- ALZN $2.06
- 52 Week High
- LDWY $6.19
- ALZN $17.73
- Technical
- Relative Strength Index (RSI)
- LDWY 50.99
- ALZN 59.32
- Support Level
- LDWY N/A
- ALZN $2.30
- Resistance Level
- LDWY $5.35
- ALZN $2.42
- Average True Range (ATR)
- LDWY 0.29
- ALZN 0.13
- MACD
- LDWY -0.25
- ALZN 0.04
- Stochastic Oscillator
- LDWY 83.20
- ALZN 95.16
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.